Eurofins Viracor and Cornell University Sign Exclusive Licensing Agreement to Expand Access to Ground-Breaking Technologies for Assessing Organ and Tissue Damage in Transplant and COVID-19 Patients
The Cornell team, led by Meinig School professor Iwijn De Vlaminck, has developed an alternative to biopsy – a novel, noninvasive blood test to measure organ injury from COVID-19. The test uses circulating cell-free DNA (cfDNA) to gauge the damage that COVID-19 inflicts on cells, tissues and organs. Read more